Exclusion criteria
bleeding, tumor, cirrhosis, chronic renal disease, hepatocellular carcinoma, benign liver tumors, chronic heart failure, ascites, cardiac cirrhosis, circulatory failure, primary cardiac disease, Ascites, cardiac disease, a reduced systolic function, nephrotoxic, uncontrolled infection, diastolic dysfunction, microhematuria, respiratory insufficiency, proteinuria, renal disease, AKI
CHRONIC HEART FAILURE, DIASTOLIC DYSFUNCTION, CARDIAC CIRRHOSIS, BLEEDING, ASCITES, TUMOR, SPONTANEOUS BACTERIAL PERITONITIS, CIRCULATORY FAILURE, RESPIRATORY INSUFFICIENCY, CIRRHOSIS, ISCHEMIC CARDIOMYOPATHY, ASCITES, RENAL DISEASE, CHRONIC RENAL DISEASE, HEPATOCELLULAR CARCINOMA, BENIGN LIVER TUMORS, CARDIAC DISEASE, HYPERTENSIVE CARDIOMYOPATHY

Patients with signs of intrinsic renal disease as defined by proteinuria (> 500 mg per day), microhematuria (> 50 red blood cells (RBC) per high power field), or signs of chronic renal disease on ultrasound.Recent or current use of nephrotoxic drugs (nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, or iodinated contrast medium) in the previous 72 h before AKI diagnosisImprovement of renal function after 2 days of diuretic removal and plasma volume expansion with albumin 1 gr/kgUncontrolled shockPatients with uncontrolled infection (defined by a 20% increase in inflammatory parameters (C-reactive protein (CRP), leucocytes or insufficient decrease of polymorphonuclear leukocytes (PMN) in ascitic fluid < 25% from baseline in the case of spontaneous bacterial peritonitis (SBP))) despite 48 h of antibiotic treatment.Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (ischemic cardiomyopathy, hypertensive cardiomyopathy, etc.)Patients with contraindications to TIPS placement (bilirubin > 5 mg/dL, recurrent hepatic encephalopathy)Patients with cavernous portal vein thrombosis, splenic vein thrombosis, or mesenteric vein thrombosisPatients with clinically significant cardiac disease (NYHA ≥ II)Patients with diastolic dysfunction grade 3Patients with a reduced systolic function with an ejection fraction ≤ 50%Patients with an acute variceal bleeding at the time of screening who have indication for pre-emptive TIPS and/or terlipressinPatients with refractory ascites as defined by the International Ascites Club (IAC) [Patients with hepatocellular carcinoma outside of the Milan criteriaPatients with hepatocellular carcinoma within the Milan criteria in whom the tumor is located in the puncture tract.Patients with benign liver tumors (except regenerative nodules) which are located in the puncture tract.Patients with other comorbidities that lead to an estimated life expectancy of under 1 year.Patients with respiratory insufficiency which requires mechanical ventilationPatients with circulatory failure which requires the administration of catecholaminesPatients receiving renal replacement therapyThe subject is currently enrolled in another investigational device or drug trialPatients with pregnancy or lactation